The case discussed is of a 38-year-old African-American woman who developed upper abdominal symptoms and liver test abnormalities. She underwent cholecystectomy for presumed gallstone disease. This was followed by a worsening of her condition, with the development of jaundice in the next 2 weeks. Results of reevaluation included transaminases around 1000 IU/L with minimal elevation of alkaline phosphatase (ALP), an antimitochondrial antibody (AMA) titer of 1:320, and an elevated immunoglobulin M (IgM). The antinuclear antibodies (ANA) level was positive, but titers were not obtained. There was no suggestion of bile duct obstruction. Liver biopsy findings were believed to be consistent with primary biliary cirrhosis (PBC). She was therefore started on, but failed treatment with, ursodeoxycholic acid. She was transferred to a transplant center 8 weeks later after a brief episode of encephalopathy and hypoglycemia. The clinical findings were consistent with subfulminant hepatic failure secondary to autoimmune hepatitis (AIH) with an ANA titer of 1:1280, an anti-smooth muscle antibody (SMA) titer of 1:40, and an elevated IgG. Review of the biopsy showed panlobular inflammation and bridging necrosis consistent with severe AIH. On imaging, she had ascites and a nodular appearance of the liver. An immediate drop in transaminases followed corticosteroid therapy, but her disease was already irreversible, and she underwent successful liver transplantation. The explanted liver was shrunken and noncirrhotic with massive hepatocellular collapse and contained multiple regenerating nodules, explaining the ultrasonographic appearances. The inflammatory component had greatly diminished compared with the earlier biopsy. The case illustrates the importance of knowledge of the natural course of a specific disease and the careful interpretation of clinical data, including autoimmune markers. PBC would rarely cause liver failure in a young woman; it is not a rapidly progressive disease. The original clinical diagnosis was unduly swayed by a positive AMA, which can be seen in up to 20% of patients with AIH. Markedly elevated transaminases with minimal elevation of ALP and positive ANA in a young woman should have pointed toward AIH at an earlier stage. The academic discussion of AMA-positive AIH versus PBC/AIH overlap syndrome remains intriguing, but prompt institution of aggressive immunosuppressive therapy aimed at the AIH component should not be deferred. In retrospect, an opportunity was missed.
3
Isogai M, Hachisuka K, Yamaguchi A.
Etiology and pathogenesis of marked elevation of serum transaminases in patients with acute gallstone disease.
HPB Surg .
1991;
4
95-107
4
Harrison H B, Middleton II M H, Crosby J H, Dasher Jr N M.
Fulminant hepatic failure: an unusual presentation of metastatic liver disease.
Gastroenterology .
1981;
80
820-25
8
Matteoni C A, Younossi Z M, Gramlich T.
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
Gastroenterology .
1999;
116
1413-1419
10
Wiesner R H.
Liver transplantation for PBC and primary sclerosing cholangitis: predicting outcome with natural history models.
Mayo Clin Proc .
1998;
73
575-588
11
Christensen E, Gunson B, Neuberger J.
Optimal timing of liver transplantation for patients with primary biliary cirrhosis: use of prognostic modeling.
J Hepatol .
1999;
30
285-292
12
Loose A W, Meyer um Buschenfelde H, Franz B.
Characterization of the overlap syndrome of primary biliary cirrhosis (PBC) and autoimmune hepatitis: evidence for it being a hepatitic form of PBC in genetically susceptible individuals.
Hepatology .
1999;
29
1078-1084
13
Chazouilleres O, Wendum D, Serfaty L.
Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy.
Hepatology .
1998;
28
296-301
15
Nikias G A, Batts K P, Czaja A J.
The nature and prognostic implications of autoimmune hepatitis with acute presentation.
J Hepatol .
1994;
21
866-871
16
Maggiore G, Porta G, Bernard O.
Autoimmune hepatitis with initial presentation as acute hepatic failure in young children.
J Pediatr Gastroenterol Nutr .
1990;
116
97-106
18 Autoimmune hepatitis: the investigational and clinical challenges. AASLD Clinical Research Single Topic Conference. Abstracts of presentations. September 16-18, 1999; Atlanta, Georgia
19
McFarlane I G.
The relationship between autoimmune markers and different clinical syndromes in autoimmune hepatitis.
Gut .
1998;
42
599-602
22
Alvarez F, Berg P A, Bianchi F B.
International Autoimmune Hepatitis Study Group report: review of criteria for diagnosis of autoimmune hepatitis.
J Hepatol .
1999;
3
929-938
23
Herzog D, Rasquin-Weber A M, Debray D, Alvarez F.
Subfulminant hepatic failure in autoimmune hepatitis type 1: an unusual form of presentation.
J Hepatol .
1997;
27
578-582
29
Shukla M, van Leeuwen J D.
Drug-induced vs.
autoimmune hepatitis? Don't delay steroids. AGC National Fellow's Forum, April 1996; Scottsdale Arizona/American College of Gastroenterology, October 1996, Abst .
30
Lam K C, Yuen P, ColbourneMJ, ChangJ, S o.
Deleterious effect of prednisolone in HBsA positive chronic active hepatitis.
N Engl J Med .
1981;
304
380
31
Czaja A, Manns M P, McFarlane I G, Hoofnagle J H.
Autoimmune hepatitis: the investigational and clinical challenges.
Hepatology .
2000;
31
1194-1200
34
Doniach D, Roitt I M, Walker J G, Sherlock S.
Tissue antibodies in primary biliary cirrhosis, active chronic lupoid hepatitis, cryptogenic cirrhosis and other liver diseases and their clinical implications.
Clin Exp Immunol .
1966;
3
237-262
37 Berg P A, Klein R. Autoantibody patterns in primary biliary cirrhosis. In: Krawitt EL, Wiesner RH, eds. Autoimmune Liver Diseases
New York: Raven Press 1991: 123-142
38
Kenny R P, Czaja A J, Ludwig J, Dickson E R.
Frequency and significance of antimitochondrial antibodies in severe chronic active hepatitis.
Dig Dis Sci .
1986;
31
705-711
42
Goulis J, Leandro G, Burroughs A K.
Randomised controlled trials of ursodeoxycholic acid therapy for primary biliary cirrhosis: a meta analysis.
Lancet .
1999;
354
1053-1060
43
Leuschner M, Maier K P, Schlichting J.
Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial.
Gastroenterology .
1999;
117
918-925
44
Angulo P, Jorgensen R A, Keach J C.
Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid.
Hepatology .
2000;
31
318-323
46
O'Grady J G, Alexander G JM, Hallyar K M, Williams R.
Early indicators of prognosis in fulminant hepatic failure.
Gastroenterology .
1989;
97
437-445
47
Neuberger J, Portmann B, Calne R, Williams R.
Recurrence of autoimmune chronic active hepatitis following orthotopic liver grafting.
Transplantation .
1984;
37
363-365
48
Sanchez-Urdazpal L, Czaja A J, van Hoek B.
Prognostic features and role of liver transplantation in severe corticosteroid-treated autoimmune chronic hepatitis.
Hepatology .
1992;
15
215-221
50
Trouillot T E, Shrestha R, Kam I.
Successful withdrawal of prednisone after adult liver transplantation for autoimmune hepatitis.
Liver Transpl Surg .
1999;
5
375-380
51
Jones D E, James O F, Portmann B.
Development of autoimmune hepatitis following liver transplantation for primary biliary cirrhosis.
Hepatology .
1999;
30
53-57